Medical device producers with advanced R&D in China to outperform peers: UOB KayHian
This is on the back of the growing availability of therapeutics and vaccines.
Some pharmaceutical firms and other research and development companies with advanced research and development on anti COVID-19 treatments and vaccines in China will outperform their peers, stemming from a demand for increasing availability of effective therapeutics and vaccines, investment banking company, UOB KayHian, said.
In its research on China’s healthcare sector, the firm sees that the strict lockdown measures will effectively mitigate the new wave of COVID-19 in China. With this, UOB KayHian pushed for increasing the availability of effective therapeutics and vaccines to improve the situation.
Due to these demands, UOB KayHian said companies with good potential for launching advanced COVID-19 treatments and vaccines will benefit and are likely to outperform.
Amongst the Chinese medical device producers that will likely become profitable are WuXi AppTec, WuXi Bio, CSPC Pharma Group, and Mindray.
UOB KayHian cited that China logged a vaccination rate of 88.1%, with 1.24 billion people receiving 3.29 billion doses of vaccines.